April 6th, 2017
FOR IMMEDIATE RELEASE
PARIS, France, and CAMBRIDGE MA. US —April 6th, 2017— Lysogene (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, announced today that Karen Aiach, CEO and Founder of Lysogene, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 11:10 am EST in Boston.
The following are specific details regarding Lysogene’s presentation:
Event: Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day
Date: April 27, 2017
Time: 11:10 am EST
Location: The State Room, 60 State Street, Boston, MA. 02109
A live video webcast of the presentation will be available at: http://www.arminvestorday.com/webcast. The webcast will be posted for further viewing on the event website following the conference.
Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at firstname.lastname@example.org. Please visit http://www.arminvestorday.com for more information.
About ARM’s Cell & Gene Therapy Investor Day
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key
therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.
Lysogene is a leading, clinical stage biotechnology company, specializing in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network, with lead products in Mucopolysaccharidosis Type IIIA and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases. Lysogene has also obtained ODD by the EMA and FDA and rare pediatric designation by the FDA for both its MPS IIIA and GM1 programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475) For more information, please visit www.lysogene.com.
|Annie-Florence Loyer||Chris Maggos|
|+ 33 6 88 20 35 59||+41 79 367 6254|
|+ 33 1 44 71 00 12|
|+ 1 (212) 223-4017|